Call us now:
Comprehensive Biologics Development Expertise
RyGen Biopharma offers integrated capabilities across the biologics development lifecycle, combining advanced scientific expertise with modern research infrastructure. Our team works across molecular design, process development, analytical characterization, and regulatory strategy to support efficient development of biologic and biosimilar therapies.
Through strong technical capabilities and regulatory-aligned development programs, we help accelerate the progression of biologics from early research to clinical development and future manufacturing readiness.
Cell Line & Clone Development
RyGen specializes in recombinant DNA design, stable clone generation, and high-producing cell line development. Our screening and selection processes ensure consistent expression, stability, and scalability required for biologics development programs.
Upstream Process Development
Our upstream development capabilities focus on optimizing cell culture conditions, media composition, and fermentation parameters to enhance productivity, product quality, and scalability for biologic manufacturing.
Downstream Process Development
We design efficient purification strategies including chromatography and filtration methods to achieve high purity, yield, and product consistency aligned with regulatory expectations.
Analytical Characterization & Bioassays
RyGen performs comprehensive analytical testing to evaluate identity, purity, potency, stability, and biosimilar comparability. Our analytical programs support product development, regulatory submissions, and quality assurance.
Regulatory & Clinical Development Support
Our team supports development programs aligned with global regulatory guidelines including CDSCO, US FDA, and EMA. We collaborate with CROs and clinical partners to advance preclinical and clinical studies while maintaining strict regulatory compliance.
Manufacturing Readiness
RyGen is establishing a cGMP-compliant biologics manufacturing facility designed to support scale-up, clinical supply, and future commercial production of biologic drug substances and drug products.